Jaguar8 commented on a stock · Nov 13, 2024 21:03

NEWS

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Tharimmune (NASDAQ:THAR) has been granted a European patent for biodegradable polymeric nanoparticles designed to deliver therapeutic antibodies and peptides. The technology aims to enhance drug delivery by improving stability and reducing systemic side effects, particularly in cancer therapies. The nanoparticles feature tunable size, non-toxic profiles, and extended drug half-life capabilities. A comparable U.S. patent application is under review. The patent complements Tharimmune's existing pipeline, including colonic targeting developed with Intract Pharma. The company is exploring strategic partnerships with antibody conjugation specialists to enhance the platform's targeting capabilities.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

4110 Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

8155

Followers

Following

93K

Visitors